Why Pradaxa?
An image denoting the 'why Pradaxa (Dabigatran)' section on the site

Pradaxa offers treatment and prevention for your patients in seven approved uses.1 On this page you’ll find information about these indications.1

Current approved uses for treatment and prevention1

An image showing the approved indications for Pradaxa (Dabigatran)






*In patients who have undergone total knee or hip replacement elective surgery.1

Stroke prevention in non-valvular atrial fibrillation (NVAF)

Pradaxa is indicated for the prevention of stroke and systemic embolism in adult patients with NVAF with one or more risk factors, such as:1

  • Prior stroke, transient ischemic attack (TIA)
  • Age ≥75 years
  • Heart failure, (NYHA Class ≥II)
  • Diabetes mellitus
  • Hypertension

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE

Pradaxa is indicated for the treatment of DVT and PE, and prevention of recurrent DVT and PE in adults.1

Primary prevention of venous thromboembolism (pVTEp)

Pradaxa is indicated for pVTEp in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.1

References: 
  1. Pradaxa Summary of Product Characteristics 2016. Boehringer Ingelheim.